Introduction
Peritoneal surface malignancy (PSM) is a common manifestation of digestive and gynecologic malignancies alike. At present, patients with isolated PSM are treated with a combination therapy of cytoreductive surgery (CRS) and hyperthermic peroperative intraperitoneal chemotherapy (HIPEC) [1] . CRS and HIPEC have evolved over three decades and have demonstrated encouraging clinical results in several phase II and III trials [2] [3] [4] [5] [6] [7] [8] [9] [10] . The combined treatment modality should now be considered standard of care for PSM from appendiceal epithelial cancers, colorectal cancer and peritoneal mesothelioma [11] [12] [13] . Promising results have also been published for HIPEC in ovarian cancer and gastric cancer [5, 9, 14] . Although there is now a clearly defined standardization of CRS, based on the work by Sugarbaker et al. [15, 16] In this manuscript, we review current data regarding drugs, doses, and durations of treatments of IP chemotherapy: standardizing HIPEC and EPIC for colorectal, appendiceal, gastric, ovarian PSM and peritoneal mesothelioma.
Selection of chemotherapy drugs for IP administration
Perhaps the most crucial aspect of an optimal IP chemotherapy treatment modality is the selection of a chemotherapy drug for use within the peritoneal space.
The ideal drug for IP chemotherapy has a high peritoneal tissue concentration; because J U S T A C C E P T E D of direct IP administration, and a high penetration into the cancer nodule. This should occur in conjunction with slow diffusion of the chemotherapy solution through the peritoneal membrane and deep in the subperitoneal space, resulting in low systemic exposure. The area-under-the-curve (AUC) ratio IP/IV is important in that it quantifies the dose intensity expected in the treatment of PSM. Table 1 summarizes the pharmacologic properties of the chemotherapy drugs most frequently selected for IP application [19] . Pharmacologic variables that should be taken into account are the route of administration, either IP only or IP combined with intravenous (IV) administration, (bidirectional intraoperative chemotherapy (BIC)). The use of naked drugs versus nanoparticles and single drugs versus multiple drugs should also be considered. To select a chemotherapy drug one must know the response expected with this drug in patients with metastatic disease. This emphasizes the increasing importance of chemosensitivity testing, towards a patients-tailored approach of selecting the ideal drug for IP and/or IV administration. At present several preclinical work has been conducted in this field using a wide variety of in vitro, in vivo and ex vivo assays using several patient-derived tumor cell-lines in combination with several chemotherapy agents [20, 21] . However, important to note is that during the in vitro assays, the 3-D structure of the tumors and hence the important pharmacodynamics of the nodules are lost.
Moreover, metabolisation which is very important for the cytotoxic effect of several drugs is not taking in to account. Ex vivo assays using patient-derived xenografts and orthotopic animal models also present an impaired view of the clinical situation. For example, implantation of tumor cells subcutaneously, due to differences in microenvironment, will result in the formation of one tumor nodule which fails to progress and metastasize. Three distinct phenotypes, two consisting of predominantly appendiceal samples (lowrisk appendiceal and high-risk appendiceal) and the third with predominately primary colorectal samples (high-risk colorectal), were identified. Furthermore, overall survival (120 months) after optimal CRS and HIPEC was significantly different between the low-risk appendiceal and the high-risk colorectal group [22] . Fujishima et al. used immunohistochemistry to evaluate mucin (MUC) protein expression in tumor nodules of patients with peritoneal dissemination from colorectal cancer as the only synchronous distant metastasis, who had received HIPEC. They report that in patients positive for MUC2 expression the 3-year overall survival rate was 0.0%, whereas in patients negative for MUC2 expression, the 3-year overall survival rate was 61.1% [23] . This emphasizes the importance of omics assays to help define better candidates for certain therapies and possibly, in the near future, the choice of chemotherapeutic agents.
Dosimetry of IP chemotherapy
The current dosing regimens of IP chemotherapy can be divided into body surface area (BSA)-based and concentration-based. Most groups use a drug dose based on calculated BSA (mg/m2) in analogy to systemic chemotherapy regimens. These regimens take BSA as a measure for the effective peritoneal contact area, the peritoneal surface area in the Dedrick formula [24] . The Dedrick formula on itself is an application of Fick's law of diffusion. Rubin et al. [25] however, demonstrated there is an imperfect correlation between actual peritoneal surface area and calculated BSA. There may also J U S T A C C E P T E D be sex differences in peritoneal surface areas, which in turn affects absorption characteristics. BSA-based IP chemotherapy will result in a fixed dose (BSA-based) diluted in varying volumes of perfusate; i.e.; different concentrations depending on substantial differences in the body composition of patients and differences in the HIPEC technique (open versus closed abdomen). From the Dedrick formula we know that peritoneal concentration and not peritoneal dose is the driving diffusion force [24] . The importance of this has been discussed by Elias et al. [26] in a clinical investigation where 2-, 4-, and 6-liters of chemotherapy solution was administered with a constant dose of chemotherapy solution. A more dilute IP chemotherapy concentration retarded the clearance of chemotherapy and resulted in less systemic toxicity [27] . Therefore, it can be assumed that by the diffusion model, less concentrated chemotherapy would penetrate to a lesser extent into the cancer nodules and normal tissues. On the other hand, concentration-based chemotherapy offers a more predictable exposure of the tumor nodules to the IP chemotherapy and thus efficacy [28] . Unfortunately, the prize to be paid for a better prediction of the efficacy of the IP chemotherapy is a high unpredictability of the plasmatic cancer chemotherapy levels and thus toxicity. Indeed, according to the Dedrick formula of transport over the peritoneal membrane, an increase in the volume of concentration-based IP chemotherapy solution will cause an increase in both diffusion surface and the amount of drug transferred from peritoneal space to plasma [29] . Currently, there is an ongoing study at our hospital evaluating both the pharmacology and morbidity of the different dosing regimens; entitled 'concentrationbased versus body surface area-based peroperative intraperitoneal chemotherapy after optimal cytoreductive surgery in colorectal peritoneal carcinomatosis treatment:
(https://clinicaltrials.gov/ct2/show/NCT03028155?term=NCT03028155&rank=1). In
this pilot study, pharmacologic parameters, the AUC ratio IP/IV and the concentrations in the tumor nodules will be correlated with 3-month overall morbidity and mortality, calculated using the Dindo-Clavien classification. Secondary endpoint is the overall 1-year survival.
Hyperthermic Intraperitoneal Peroperative Chemotherapy (HIPEC)
HIPEC is the most widely explored modality that has consistent clinically improved outcomes in many phase II and III trials [2, 3, [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] . The drugs that are used in this setting are non cell-cycle specific drugs, which make them applicable for single instillation as in HIPEC ( doxorubicin has generated interest for HIPEC application due to its favorable pharmacokinetics [82, 83] . Doxorubicin-based HIPEC has been used in PSM from appendiceal, gastric, ovarian and colon cancer, as well as in peritoneal mesothelioma [4, [84] [85] [86] .
Bidirectional Intraoperative Chemotherapy (BIC)
By combining intraoperative IV and intraoperative IP cancer chemotherapy, a bidirectional diffusion gradient is created through the intermediate tissue layer Proper selection of chemotherapy agents based on pharmacologic principles suggests the use of cell-cycle specific drugs such as 5-fluorouracil and the taxanes (Table 3) Table 3 .
Taxanes
Paclitaxel and docetaxel, with their high molecular weight these molecules, have a remarkable high AUC ratio of respectively 853 and 861 [19] . The taxanes stabilize the microtubule against depolymerization; thereby disrupting normal microtubule dynamics [98] . There is evidence supporting additional mechanisms of action [99] . They exert cytotoxic activity against a broad range of tumors. This translates itself into a clear pharmacokinetic advantage for IP administration [100] . The data regarding possible thermal augmentation of taxanes are conflicting [99] . Taxanes 
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bioavailability are under investigation [101] . The current regimens for EPIC with paclitaxel are presented in Table 3 .
Monoclonal antibodies and avastin
Angiogenesis, the growth of new blood vessels from pre-existing vessels, is paramount for tumor growth and the formation of metastases. It is induced through the production of angiogenic factors by tumor cells [102, 103] . A key player in this process is vascular endothelial growth factor-A (VEGF-A), which binds to its receptors VEGFR-1 and VEGFR-2 and thereby increases endothelial cell survival, proliferation, migration and differentiation [104, 105] . [114, 115] . They report that VEGF is present in the peritoneal cavity of patients with PSM treated with curative intent, and its levels increase after CRS. Neoadjuvant bevacizumab significantly decreased the preoperative IP VEGF levels. However, neoadjuvant IV bevacizumab was associated with increased major morbidity [116] . They concluded that the use of preoperative IP bevacizumab for patients with extensive disease burden should be considered, especially in colorectal PSM. Other targeted molecular therapies include the use of drugs that inhibit the endothelial growth factor receptor (EGFR)-related factors to control tumor cell proliferation and differentiation. These drugs include cetuximab and panitumumab [117, 118] . 
Future directions in IP chemotherapy

Neoadjuvant Intraperitoneal and Systemic Chemotherapy (NIPS)
Neoadjuvant
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reported to add to morbidity and mortality of further surgical treatment [123] .
Furthermore, extensive fibrosis, as a response to chemotherapy, may occur and render judgments concerning the extent of PC difficult or impossible.
Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC)
Pressurized intraperitoneal aerosol chemotherapy (PIPAC) is a novel approach to deliver IP chemotherapy to patients diagnosed with PSM [124] . During PIPAC, a normothermic capnoperitoneum (pressure of 12 mmHg) is established through a laparoscopic access in an operating room equipped with a laminar airflow. A cytotoxic solution is nebulized into the abdominal cavity during 30 minutes and thereafter removed through a closed suction system [125] . The hypothesis underlying this technique is that intraabdominal application of chemotherapy under pressure will enhance tumor drug uptake and aerosolizing and spraying chemotherapy will enhance the area of peritoneal surface covered by the drug.
Several experimental and clinical studies have been conducted to test the abovementioned hypothesis [125] [126] [127] [128] [129] . Solass et al. performed PIPAC with cisplatin and doxorubicin in 3 end-staged patients with advanced PC of gastric, appendiceal and ovarian origin. They report that PIPAC required only 1/10 of the doxorubicin dose to achieve higher tumor concentrations as compared to HIPEC. High tissue concentrations of doxorubicin were reported. Moreover, fluorescence microscopy showed nuclear presence of doxorubicin throughout the whole peritoneal layer and up to deeply into the retroperitoneal fatty tissue. They concluded that PIPAC was well tolerated with excellent local exposure and low systemic exposure [127] . Moreover, PIPAC appeared to be associated with very limited hepatic and renal toxicity even after repeated PIPAC [130, 131] . On the other hand, Khosrawipour et al. reported that the depth of J U S T
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doxorubicin penetration was significantly higher in tissues directly exposed to the aerosol jet when compared to the side wall, in an ex vivo PIPAC model [132] . Repeated PIPAC with oxaliplatin could induce regression of the peritoneal metastases, with low toxicities [133] . However, it should be taken into account that patients included in these trials are highly selected and often have had extensive surgery and were already heavily pretreated with several lines of systemic chemotherapy. The potential limited access of the aerosolized chemotherapy due to the presence of adhesions is not taken into account. Moreover, incomplete responses warrants further cytoreduction. However, it has been reported that PIPAC should not be combined with CRS due to the potential of increased local toxicity [134] . Recently, Kakchekeeva et al.
introduced electrostatic PIPAC (ePIPAC), hypothesizing that electrostatic charging the aerosol particles may further enhance the pharmacologic properties of PIPAC [135] .
They performed a comparative study of PIPAC and ePIPAC assessing the pharmacologic properties using an in vivo porcine model. They reported that ePIPAC has the potential to allow more efficient drug uptake, further dose reduction, a significant shortening of the time required for PIPAC application, further improving health and safety measures.
Today, there are no phase III trial data available for PIPAC emphasizing that J U S T
this is still an experimental treatment, which should be further investigated within the context of controlled clinical trials. These data will be important in identifying the role of PIPAC in the treatment of PSM patients. Today, PIPAC can play a role as a new palliative treatment option in highly selected patients with PSM.
Drug delivery systems
As was previously mentioned, the ideal drug for IP chemotherapy should have a high peritoneal tissue concentration and this should occur in conjunction with slow diffusion of the chemotherapy solution through the peritoneal membrane and deep in the subperitoneal space. However, today there are no drugs specifically designed for IP use. Therefore, over the past years, a lot of research has been focusing on the use of drug delivery systems to optimize IP drug delivery and to prolong the residence time of the drug in the peritoneal cavity with minimal systemic toxicity. These delivery systems include microspheres, nanoparticles, liposomes, micelles, injectable systems and implantable systems [101, 136] . In a preclinical study, De Smet et al. reported the development of a stable nanocrystalline paclitaxel formulation which was of interest for the treatment of ovarian PSM via HIPEC [137] . Xu et al. designed a thermosensitive injectable drug delivery hydrogel assembled by paclitaxel-incorporated nanoparticles with an improved bioavailability and induced effective antitumor efficacy in a colorectal PSM mouse model [138] . Thermosensitive hydrogels can transfer from freeflowing sol to a gel at physiological temperature and are interesting candidates for sustained drug delivery.
Conclusion
The combination of CRS and IP chemotherapy should now be considered standard of care for PSM from appendiceal epithelial cancers, colorectal cancer and 
